Literature DB >> 17196853

Gaucher disease among Chinese patients: review on genotype/phenotype correlation from 29 patients and identification of novel and rare alleles.

Francis Y M Choy1, Weimin Zhang, Hui-Ping Shi, Agnes Zay, Tessa Campbell, Nelson Tang, Patrick Ferreira.   

Abstract

Gaucher disease, the most prevalent lysosomal storage disease, results from an inherited deficiency in the enzyme glucocerebrosidase. Three clinical forms of Gaucher disease have been described: Type 1 non-neuronopathic, Type 2 acute neuronopathic, and Type 3 subacute neuronopathic. Although Gaucher disease is panethnic, its presentation reveals some ethnic-specific characteristics. The Type 1 form is most common among Caucasian patients. In contrast, the majority of Chinese Gaucher disease patients have early age of onset, severe hematological and skeletal complications, and often neurological involvement, resulting in early childhood death. In this report, we review 29 cases of Gaucher disease from 23 unrelated patients and 6 patients from 3 non-consanguineous families. Among these patients, 13 were diagnosed as Type 1, 10 as Type 2, and 6 as Type 3. A novel mutation, del 205-209ACCTT, was identified in the heterozygous form with mutation R353W (c.1174C>T) by DNA sequence analysis in 2 Type 1 patients who are sibs. Mutation R353W was also found in the heterozygous form in 3 other Type 1 patients, with mutation L444P in 2 sibs and a second unknown Gaucher allele in the third patient. The Gaucher genotypes of the remaining Type 1 patients were F37V/L444P, G46E/L444P, R48W/R120W, N188S/L444P, Y205C/L444P, N370S/L444P, and L444P/unknown. It was noted that mutation N370S in the patient was linked to the pv1.1(-)(1) haplotype present in Jewish patients. Among the Type 2 patients, L444P was present in the heterozygous form with mutation F213I, L385P, or the complex allele (RecNci) in 5 patients. The second most common mutation, F213I, was found in the heterozygous form in 6 patients with mutations N382K, L383R, or L444P. The other mutations found in the Type 2 patients were P122L, V375L, Y363C, M416V, and 383-400del. The genotypes of the 6 Type 3 patients identified were D409H/D409H, D409H/G202R, G46E/N188S, N188S/unknown, and L444P/L444P. While D409H has been reported as being associated with cardiovascular/ocular involvements in Gaucher disease, there have been no such complications in these patients. As noted, the majority of the Gaucher mutations we identified in the Chinese patients were either rare or absent in other populations. With the exception of N370S and R353W found only in the Type 1 form, the majority of these mutations are severe ones that result in poor prognosis and often Types 2 and 3 Gaucher disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17196853     DOI: 10.1016/j.bcmd.2006.11.003

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  25 in total

1.  Glucosidase acid beta gene mutations in Egyptian children with Gaucher disease and relation to disease phenotypes.

Authors:  Zakarya El-Morsy; Mohamed T Khashaba; Othman El-Sayed Soliman; Sohier Yahia; Dina Abd El-Hady
Journal:  World J Pediatr       Date:  2011-06-01       Impact factor: 2.764

2.  The neurological manifestations of Gaucher disease type 1: the French Observatoire on Gaucher disease (FROG).

Authors:  P Chérin; C Rose; C de Roux-Serratrice; D Tardy; D Dobbelaere; B Grosbois; E Hachulla; R Jaussaud; R-M Javier; E Noël; P Clerson; A Hartmann
Journal:  J Inherit Metab Dis       Date:  2010-06-02       Impact factor: 4.982

3.  GBA mutations in Gaucher type I Venezuelan patients: ethnic origins and frequencies.

Authors:  Gilberto Gómez; Sergio Arias; Leonor Cárdenas; Dalal Zoghbi; Irene Paradisi
Journal:  J Genet       Date:  2017-09       Impact factor: 1.166

4.  Intravenous infusion of iPSC-derived neural precursor cells increases acid β-glucosidase function in the brain and lessens the neuronopathic phenotype in a mouse model of Gaucher disease.

Authors:  Yanyan Peng; Benjamin Liou; Venette Inskeep; Rachel Blackwood; Christopher N Mayhew; Gregory A Grabowski; Ying Sun
Journal:  Hum Mol Genet       Date:  2019-10-15       Impact factor: 6.150

5.  Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the International Collaborative Gaucher Group Neurological Outcomes Subregistry.

Authors:  Anna Tylki-Szymańska; Ashok Vellodi; Amal El-Beshlawy; J Alexander Cole; Edwin Kolodny
Journal:  J Inherit Metab Dis       Date:  2010-01-19       Impact factor: 4.982

6.  Identification of pharmacological chaperones for Gaucher disease and characterization of their effects on beta-glucocerebrosidase by hydrogen/deuterium exchange mass spectrometry.

Authors:  Michael B Tropak; Gregory J Kornhaber; Brigitte A Rigat; Gustavo H Maegawa; Justin D Buttner; Jan E Blanchard; Cecilia Murphy; Steven J Tuske; Stephen J Coales; Yoshitomo Hamuro; Eric D Brown; Don J Mahuran
Journal:  Chembiochem       Date:  2008-11-03       Impact factor: 3.164

7.  A novel genotype c.1228C>G/c.1448C-1498C (L371V/Rec-NciI) in a 3-year-old child with type 1 Gaucher disease.

Authors:  Nabil A Yassin; Samar A Muwakkit; Ahmad O Ibrahim; Imad M Kayim; Mohammad-Zohair M Habbal; Nabil M Chamseddine; Khaled M Musallam; Ali I Shamseddine
Journal:  J Appl Genet       Date:  2008       Impact factor: 3.240

8.  Novel pathogenic mutations in the glucocerebrosidase locus.

Authors:  Raquel Duran; Alisdair McNeill; Atul Mehta; Derralyn Hughes; Timothy Cox; Patrick Deegan; Anthony H V Schapira; John Hardy
Journal:  Mol Genet Metab       Date:  2012-05-18       Impact factor: 4.797

9.  Gaucher disease and cancer: concept and controversy.

Authors:  Francis Y M Choy; Tessa N Campbell
Journal:  Int J Cell Biol       Date:  2011-06-07

10.  Glucocerebrosidase L444P mutation confers genetic risk for Parkinson's disease in central China.

Authors:  Youpei Wang; Ling Liu; Jing Xiong; Xiaowei Zhang; Zhenzhen Chen; Lan Yu; Chunnuan Chen; Jinsha Huang; Zhentao Zhang; Asrah A Mohmed; Zhicheng Lin; Nian Xiong; Tao Wang
Journal:  Behav Brain Funct       Date:  2012-12-10       Impact factor: 3.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.